By John J. Castellani - 11/02/11 11:23 PM EDT
In 1981 the first cases of AIDS in America were detected in California and New York. Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS. While this is remarkable progress, it’s not enough. The biopharmaceutical research industry remains deeply committed to developing new treatments — and eventually a cure.
HIV/AIDS and other opportunistic infections often take a greater toll on those who don’t live on our shores. But millions of lives around the globe have been eased and even saved thanks to more than 115 antiretroviral (ARV) therapies for opportunistic infections that have been brought to market.
Pharmaceutical Research and Manufacturers of America’s (PhRMA) member companies have supported PEPFAR since its inception, and the TPP agreement does nothing to alter that support. So far, the FDA has “approved” for the purposes of PEPFAR more than 265 generic versions of patented drugs now being produced outside of the United States. The vast majority of the medicines purchased by PEPFAR, in fact, are generic versions of medicines created by biopharmaceutical research companies and still under patent protections.
We believe the TPP negotiators are fully committed to maintaining the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The bottom line is that if governments and international agencies wish to purchase safe and effective drugs through the PEPFAR mechanism, the proposed TPP plan does nothing to change this. But what is certain is that without appropriate intellectual property protection, further innovations and needed research, progress could be slowed and in some areas stopped — and it is patients who will lose out.
Our scientists are hard at work in labs each day to develop the next revolutionary treatment that could save patients’ lives. But we all must recognize that the problem with fighting these brutal diseases in developing countries is not simply a lack of accessible treatment. Insufficient infrastructure — weak healthcare systems, lack of transportation, lack of trained healthcare personnel — is an enormous roadblock to any significant progress. Recognizing these multi-dimension problems requires broad-based solutions.
The biopharmaceutical sector acts as a partner in health in these countries. In both 2007 and 2008, for example, U.S. biopharmaceutical companies contributed more than the combined health budgets of USAID, the World Bank and the World Health Organization. In addition, companies including Pfizer, Bristol Myer-Squibb and Abbott Laboratories have constructed hospitals, clinics and an infectious disease institute to help train Africa’s AIDS cadres.
The biopharmaceutical research industry remains steadfast in combating HIV/AIDS: The industry is currently developing around 100 new medicines and vaccines to help treat HIV. Further, more than 10 of the top research-based pharmaceutical organizations have issued voluntary licenses to developing countries for local production of ARV drugs so patients can access treatments more swiftly.
For every two patients who begin HIV treatment, five more are infected. The HIV/AIDS epidemic is a complex problem, and we in the biopharmaceutical research industry know as well as anyone that it will require a complex solution. We will find a cure eventually, but in the meantime, we must work together to ensure that progress continues across the healthcare system so the millions of patients suffering today have a hope of a better tomorrow.
Castellani is CEO and president of Pharmaceutical Research and Manufacturers of America.